KRAS and neoplasm: In a meta-analysis by Blysma L et al. of 44 studies involving 15,981 patients from 17 European, 11 Asian, 9 US, 3 Australian, and 4 multi-country studies, the incidence of KRAS/BRAF mutations differed significantly according to tumor localization.